David Lennon

Novartis Pharma KK develops, imports, produces and sells pharmaceutical products. The company was founded on April 1, 1997 and is headquartered in Tokyo, Japan.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL.

Satellite Biosciences, Inc. is a company based in Cambridge, MA that is focused on developing innovative regenerative medicine solutions to tackle some of the most challenging diseases. The company's mission is to create a new category of regenerative medicine called Tissue Therapeutics. The company was founded by Sangeeta N. Bhatia, Christopher S. Chen, and Arnav Chhabra. David Lennon has been the CEO of the company since 2021.